Many ALK-TKIs have been validated since the first EML4-ALK fusion in NSCLC was discovered, and their use in clinical practice has significantly improved PFS and OS in patients with metastatic ALK-positive NSCLC [22]. This evidence concerns the gene EML4 and non-small cell lung carcinoma.